Table 1.
Characteristics of study cohort at baseline (n = 32)
| Characteristic | n (%) unless indicated otherwise |
|---|---|
| Age in years, median (range) | 63 (37–86) |
| Sex | |
| Male | 23 (72%) |
| Female | 9 (28%) |
| BMI, median (range) | 26 (20–38) |
| Primary site | |
| Colon | 23 (72%) |
| Rectum | 9 (28%) |
| Definitive treatment to primary tumour | 26 (81%) |
| Hepatic tumour burdena, median (range) | 9 (1–46) |
| Hepatic tumour burdena > 25% | 4 (13%) |
| Extrahepatic metastasesb | 23 (72%) |
| Location of extrahepatic metastases | |
| Lungs alone | 13 |
| Lung and lymph nodes | 2 |
| Lymph nodes alone | 5 |
| Other | 3 |
| Prior therapies | |
| Lines of chemotherapy 1 |
9 (28%) |
| 2 | 22 (69%) |
| Anti-VEGF/EGFR mAb | 28 (88%) |
| Hepatic resection | 11 (34%) |
| RFA/SBRTc to liver | 2 (6%) |
| Isolated liver oxaliplatin | 1 (3%) |
| Radiotherapy to extrahepatic sites | 6 (19%) |
| RAS mutation statusd | |
| Wild type | 14 (44%) |
| Mutant | 10 (31%) |
| Unknown | 8 (25%) |
| Treatment to both liver lobes | 19 (59%) |
| Prescribed amount of 90Y for treatment in GBq, median (range)e | 1.68 (0.42–2.08) |
| Time to follow-up FDG PET/CTe in days, median (range) | 56 (38–80) |
aAs measured by the MeVis® radiological service (MeVis Medical Solutions AG, Bremen, Germany), based on contrast enhanced CT performed at the time of baseline FDG PET/CT
bDetected on FDG PET/CT
cRFA, Radiofrequency ablation; SBRT, stereotactic body radiation therapy
dKRAS/NRAS where tested
eFrom sub-cohort of 22 patients with analysable lesion data only